Metagenomi (MGX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• May 12, 2026: Metagenomi is projected to report Q1 2026 results on May 12, with analysts forecasting EPS of ($0.60) and revenue of $5.903 million, and an earnings call scheduled for 4:00 PM ET.
• The company recently missed estimates—reporting ($0.60) EPS (vs. $0.58 expected) and $3.91 million revenue—and shows strained fundamentals with a negative net margin (−348.54%) and analysts forecasting about ($2.00) EPS for the fiscal year.
• Shares trade near $1.42 with a market cap of $53.46 million, yet the consensus rating is a "Moderate Buy" with an average target price of $10.00, and several institutions (Bank of America, AQR, Norges Bank, Marshall Wace, Jane Street) have recently built or increased stakes.

Metagenomi (NASDAQ:MGX - Get Free Report) is projected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $5.9030 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Metagenomi (NASDAQ:MGX - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.02). The firm had revenue of $3.91 million for the quarter, compared to analysts' expectations of $7.33 million. Metagenomi had a negative net margin of 348.54% and a negative return on equity of 47.14%. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Metagenomi Price Performance

MGX traded up $0.01 during trading on Tuesday, hitting $1.42. 23,108 shares of the stock traded hands, compared to its average volume of 232,190. The firm has a market capitalization of $53.46 million, a P/E ratio of -0.60 and a beta of 0.63. The firm has a 50-day moving average of $1.46 and a 200 day moving average of $1.72. Metagenomi has a 12-month low of $1.25 and a 12-month high of $3.95.

Analysts Set New Price Targets

MGX has been the subject of several analyst reports. Wall Street Zen cut shares of Metagenomi from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. Weiss Ratings raised shares of Metagenomi from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.00.

Institutional Trading of Metagenomi

A number of institutional investors and hedge funds have recently bought and sold shares of MGX. Bank of America Corp DE increased its stake in Metagenomi by 482.9% during the 4th quarter. Bank of America Corp DE now owns 21,113 shares of the company's stock valued at $76,000 after purchasing an additional 17,491 shares in the last quarter. AQR Capital Management LLC bought a new stake in Metagenomi during the 1st quarter valued at about $119,000. Norges Bank bought a new stake in Metagenomi during the 2nd quarter valued at about $373,000. Marshall Wace LLP bought a new stake in Metagenomi during the 2nd quarter valued at about $222,000. Finally, Jane Street Group LLC bought a new stake in Metagenomi during the 2nd quarter valued at about $235,000.

Metagenomi Company Profile

Metagenomi, Inc NASDAQ: MGX is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company's proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi's technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.